MIDATECH PHARMA
R&D | Opsisporin

Opsisporin for Uveitis

Uveitis is an inflammatory process affecting the iris, the ciliary body, the choroid layer or all or part of these structures of the eye. Significant vision loss can occur in up to 35% of children and adults with uveitis and total blindness as a result of uveitis accounts for 10% to 15% of all cases. Midatech is using its Q-Sphera sustained release technology to develop OpsiSporin, a sustained release cyclosporine, for use in uveitis. Current treatments for uveitis such as systemic or local immunosuppressants and corticosteroids have limited efficacy and very poor side-effect profile, has yet to be brought to market – this is the objective of OpsiSporin.

This project is anticipated to reach clinical stage in the second half of 2017. Clinical development is likely to be conducted through Phase IB and Phase II studies, with marketing authorisation filings potentially being approved in 2019.

R&D
R&D
Opsisporin

Opsisporin for Uveitis

Uveitis is an inflammatory process affecting the iris, the ciliary body, the choroid layer or all or part of these structures of the eye. Significant vision loss can occur in up to 35% of children and adults with uveitis and total blindness as a result of uveitis accounts for 10% to 15% of all cases. Midatech is using its Q-Sphera sustained release technology to develop OpsiSporin, a sustained release cyclosporine, for use in uveitis. Current treatments for uveitis such as systemic or local immunosuppressants and corticosteroids have limited efficacy and very poor side-effect profile, has yet to be brought to market – this is the objective of OpsiSporin.

This project is anticipated to reach clinical stage in the second half of 2017. Clinical development is likely to be conducted through Phase IB and Phase II studies, with marketing authorisation filings potentially being approved in 2019.

© Copyright 2017 Midatech Pharma PLC